Hormonal Contraceptives Market Definition

The hormonal contraceptives market consists of sale of hormonal contraceptives and related services by entities (organizations, sole traders, and partnerships) that produce hormonal contraceptives that are used as a birth control method acting on the endocrine system of the human body to prevent pregnancy. Hormonal contraceptives refers to birth control methods that act on the endocrine system and regulates the hormonal cycle using estrogens and progestogens to prevent pregnancy in women (there are currently no approved hormonal contraceptives for use in men). Hormonal contraceptives are available in different forms such as pills, injections, implants, and intrauterine devices and contain a small amount of human-made estrogen and progestogen hormones. These hormones inhibit the natural menstrual cycle and prevent pregnancy.

Gynecology Drugs Market Definition

The gynecology drugs market consists of sales of gynecology drugs by entities (organizations, sole traders, and partnerships) that manufacture gynecology drugs that are used to treat gynecological diseases, which includes conditions affecting the uterus, ovaries, and their appendages. Gynecology is the branch of medicine that deals with the health of the female reproductive system as well as diagnosis and treatment female reproductive organ diseases. Gynecologists are physicians specialized in treating these diseases and providing well-woman health care focused on the reproductive organs.

The cold and cough preparations refer to the medications that are used to treat cold and cough. The drugs for the treatment of cold and cough act on the receptors to which the virus causing the infection gets attached, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines are drugs or other compounds that block the physiological effects of histamine and are used to treat allergies in particular. The different types include bronchodilators, anticholinergic, and pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and drug stores. The cold and cough preparations market research report is one of a series of new reports from The Business Research Company that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cough and cold preparations market size will grow from $66.75 billion in 2022 to $70.37 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cough and cold preparations market size is expected to grow to $84.02 billion in 2027 at a CAGR of 4.5%. The rising incidence of allergies is expected to fuel the growth of the cough and cold preparations market in the forecast period. There are many respiratory allergies such as pollen, dust, mold, and pet allergies; these allergies are caused due to contaminated outdoor and indoor air. Cough and cold preparations are consumed for treating allergies, which cause cough and cause issues in the respiratory tract. For instance, according to the European Academy of Allergy and Clinical Immunology, a non-profit organization for European clinicians, researchers, and allied health professionals, by 2025, 1 in every 3 people in the European Union is expected to be affected by allergies. Thus, the increase in the incidence of respiratory allergies will bolster the demand for cough and cold preparations, positively affecting the growth of the market. Threat from substitute products such as generic and counterfeit drugs is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in the drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs is manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article by Alpha InvesCo., a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, counterfeits made with low-grade materials can destroy the reputations of legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to a global life sciences report by Deloitte, the adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators that are objectively measured and evaluated for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing, and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2022. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the global cold and cough preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

Smart pills are used to deliver medication and are equipped with electronic sensors that emit signals to be captured by patches or smartphones when they are swallowed. These pills ensure drug regimen compliance and help track medication adherence of patients. The main applications of smart pills are capsule endoscopy, patient monitoring, and drug delivery, patient monitoring involves the repeated or continuous observations or measurements of the patient parameters. These pills are used to target the esophagus, stomach, small intestine, and large intestine to treat diseases such as esophageal diseases, colon diseases, small bowel diseases, and others. Smart pills are used by various end-users such as hospitals, diagnostic centres, and research institutes. The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart pills market size will grow from $4.48 billion in 2022 to $4.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart pills market size is expected to grow to $7.61 billion in 2027 at a CAGR of 11.2%. The growing preference for non-invasive procedures is driving the smart pills market. The non-invasive procedures are diagnostic and treatment procedures that do not require an incision on the body or removal of tissues for the treatment or diagnosis. Smart pill is a wireless, ingestible capsule that can be easily swallowed and has a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For instance, smart pills have key applications in diagnostic imaging such as capsule endoscopy. The capsule endoscopy is a diagnostic procedure in which a smart pill (capsule enclosed micro-camera) is swallowed and images of the esophagus, stomach, and small intestine can be taken as the device pass through your gastrointestinal (GI) tract. Smart pills have revolutionized the diagnosis of gastrointestinal disorders and could replace conventional diagnostic techniques such as endoscopy. Therefore, non-invasive procedures are driving the smart pills market during the period. The high cost of smart pills associated with technological advancement will act as a restraint to the market growth. The utilization of advanced technologies including software up-gradation and innovative systems, and the integration of microchips contribute to the high manufacturing costs of the smart pills. Smart pills are a combination of drug and device technology. A smart pill is an innovative method of drug delivery, which involves the use of sensors and cameras embedded into tiny edible devices. Such medical devices ensure better diagnostics, monitoring, and treatment of life-threatening medical conditions by allowing doctors to monitor their patients’ body functions in real-time. However, the high cost of smart pills led to the limited utilization of products in underdeveloped countries. Thus, the high cost is considered as one of the factors that restrain the growth of the small pills market. Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills. ATOMS are silicon chip devices that use the principle of magnetic resonance imaging (MRI) to determine the location of atoms in a patient’s body using magnetic fields. ATOMS can be used in ingestible smart pills to diagnose and treat diseases from within the body. The devices can be used to monitor a patient’s gastrointestinal tract, blood, or brain. They also could measure factors that indicate the health of a patient such as pH, temperature, pressure, and sugar concentrations, and relay that information to doctors. The devices could even be instructed to release drugs. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip that can be used as a smart pill. Major players in the smart pills market are Medtronic PLC., Olympus Medical Technology, CapsoVision, Inc., Novartis AG, Proteus Pharmaceuticals, Philips Healthcare, Microchips, Bio-Images Drug Delivery (BDD) Limited, Given Imaging, Inc., and Vitality. North America was the largest region in the smart pills market in 2022. Western Europe was the second-largest region in the global smart pills market. The regions covered in the global smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart pills market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart pills market is segmented - 1) By Application: Capsule Endoscopy, Patient Monitoring, Drug Delivery 2) By End User: Hospital, Diagnostic Center, Research Institute 3) By Target Area: Esophagus, Stomach, Small Intestine, Large Intestine 4) By Disease Indication: Esophageal Diseases, Colon Diseases, Small bowel Diseases, and Other Disease Indications

Oral contraceptive pills refer to a contraceptive tablet that contains hormones that prevent the release of eggs from the ovaries. Oral contraceptives typically contain progestin and oestrogen. Also known as the "birth control pill," it comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin.   The oral contraceptive pills market by type into the combination, progestin-only, others; by category into generic, branded; by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others. The oral contraceptive pills market research report is one of a series of new reports from The Business Research Company that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with an oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral contraceptive pills market grew from $20.13 billion in 2022 to $21.61 billion in 2023 at a compound annual growth rate (CAGR) of 7.35%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral contraceptive pills market size is expected to grow to $36.09 billion in 2027 at a CAGR of 13.68%. The high incidence of unintended pregnancies is expected to drive the growth of the oral contraceptive pills market over the coming years. Unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low-middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed that 4,794 women had unplanned pregnancies after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market. The side effects associated with the use of contraceptive drugs are expected to hinder the growth of the oral contraceptive pills market over the forecast period. An oral contraceptive pill is a hormonal procedure to avoid childbirth. The side effects vary between people and the type of pill consumed. Breast tenderness, headaches, spotting, and nausea are some prominent side effects of oral contraceptive pills. Depo-Provera, an implantable contraceptive, is known to provide the most severe side effects. Research has indicated that Depo-Provera and Depo-SubQ Provera 104 can trigger bone mineral density loss. The U.S. Food and Drug Administration (FDA) attached strict notices to the injection kit saying Depo-Provera and Depo-SubQ Provera 104 could not be used for more than 2 years, attributing to their side effects. The notice also suggests that the use of these medications may increase the risk of osteoporosis and bone disorders later in life. Hence, the side effects associated with the use of contraceptive drugs hamper the growth of the oral contraceptive pill market. Major institutes and companies operating in the oral contraceptive pill sector are focusing on developing innovative solutions for oral contraceptive pills. For instance, in July 2022, HRA Pharma, a France based innovative healthcare company, developed an over the-counter birth control pill called "Opill." HRA Pharma has submitted an application to the Food and Drug Administration in the United States. Opil is a progestin-based contraceptive that helps people access contraception without facing any difficulty. In January 2020, Theramex, a speciality pharmaceutical company for women announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck &Co for an undisclosed amount. This acquisition aids Theramex in global expansion and adding innovative treatment options for women to its portfolio. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio. Major players in the contraceptive pills market are Teva Pharmaceutical Industries Ltd., Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson, and Lupin Pharmaceuticals Inc. North America was the largest region in the oral contraceptive pills market in 2022. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral contraceptive pills market is segmented - 1) By Type: Combination, Progestin Only, Other Types 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels

Women’s health devices refer to devices that enable them to take control of their health and health-related data with at-home tests and other features. The women’s health devices are used to enhance women's healthcare, including maternal and menstrual health, pelvic and sexual health, fertility, menopause, and contraception, as well as many general health disorders that affect women disproportionately or differently, such as osteoporosis or cardiovascular disease. The main product types of women’s health devices are surgical, diagnostics, contraceptives, labor and delivery, and critical care. A surgical device refers to a specialized device used by surgeon to relieve a medical condition. The applications of women’s health devices include cancer, osteoporosis, infectious disease, uterine fibroids, post-menopausal syndrome, pregnancy, female sterilization, and other applications. The various end-users of women’s health devices include hospitals, obstetrics and gynecology clinics, diagnostic laboratories, ambulatory surgical centers, and other end users. The women’s health devices market research report is one of a series of new reports from The Business Research Company that provides women’s health devices market statistics, including women’s health devices industry global market size, regional shares, competitors with a women’s health devices market share, detailed women’s health devices market segments, market trends and opportunities, and any further data you may need to thrive in the women’s health devices industry. This women’s health devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global women’s health devices market size grew from $33.89 billion in 2022 to $36.95 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The women’s health devices market size is expected to grow to $52.54 billion in 2027 at a CAGR of 9.2%. An increase in government programs aimed at raising awareness about women’s health is contributing to the growth of the women’s health devices market going forward. Government programs aimed at raising awareness about women’s health refer to initiatives and awareness events organized by the government to make the population aware of some societal boosting the public healthcare system's efficiency and effectiveness. These government programs help in creating awareness, which in turn increases the need for women's health devices for easy diagnosis. For instance, in March 2022, according to the Department of Health, Victoria, the Victorian government released its first-ever women’s sexual and reproductive health strategy and priority action plan for women’s sexual and reproductive health. The plan is supported by a $6.6 million investment for action and education to reduce stigma and improve knowledge of sexual and reproductive health and other such issues. Therefore, an increase in government programs aimed at raising awareness about women’s health is expected to boost demand for women’s health devices during the forecast period. Technological advancement is a key trend gaining popularity in the women’s health devices market. Many companies operating in the women’s health devices sector are looking for new technologies to strengthen their position in the women’s health devices market. For instance, in May 2022, iSono Health, a US-based medical equipment manufacturing company, launched ATUSA, which is the world’s first portable and automated 3D breast ultrasound scanner. This combines a unique 3D ultrasound scanner with artificial intelligence to perform full breast scans and accurately locate breast tumors. It automatically captures the entire breast volume, allowing for unremarkable breast ultrasound imaging at the point of care without the need for a trained ultrasound driver. This launch represents another step forward for the company and the female population. In February 2022, CooperSurgical, a US-based women’s healthcare brand, acquired Cook Medical's reproductive health portfolio for an amount of $875 million. With this acquisition, both companies aim to invest in future growth and new technologies. Cook Medical is a US-based company that manufacturers invasive medical devices for fertility, obstetrics, gynaecology, in vitro fertilization, and assisted reproductive technology. Major players in the women’s health devices market are Abbott Laboratories, Koninklijke Philips N.V., CooperSurgical, F. Hoffmann-La Roche, Caldera Medical, GE Healthcare, Carestream Health, Hologic, Medline Industries, Candence Inc., Boston Scientific Corporation, Reckitt Benckiser, BD. Com, Coloplast A/S, and MedGyn Products, Inc. North America was the largest region in the women’s health devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the women’s health devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the women’s health devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The women’s health devices market consists of sales of contraceptive devices and pharmaceuticals, densitometry, breast implants, obstetrics/gynecology biopsy and imaging. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global womens health devices market is segmented - 1) By Product: Surgical, Diagnostics, Contraceptives, Labor and Delivery, Critical Care 2) By Type: Devices, Consumables 3) By Application: Cancer, Osteoporosis, Infectious Disease, Uterine Fibroids, Post-menopausal Syndrome, Pregnancy, Female Sterilization, Other Applications 4) By End-user: Hospitals, Obstetrics and Gynaecology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centres, Other End Users

Polycystic ovarian syndrome is a disorder in which hormones are out of control for females and they have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them. The main drug types in the polycystic ovarian syndrome treatment market are oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based drugs that are taken orally to prevent pregnancy. They prevent pregnancy by slowing ovulation and preventing sperm from entering the cervix. The various surgery types include ovarian wedge resection and laparoscopic ovarian drilling, which are performed in hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers. The polycystic ovarian syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global polycystic ovarian syndrome treatment market will grow from $4.26 billion in 2022 to $4.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global polycystic ovarian syndrome treatment market is expected to grow to $5.66 billion in 2027 at a CAGR of 5.9%. The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market. Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market. FDA has not approved pharmacological treatment for use in adolescents with PCOS. However, some pharmacological interventions are used to treat PCOS symptoms. For instance, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved by the United States Food and Drug Administration (FDA) in the USA due to concerns about suicidal ideation and drug overdoses. Moreover, Minoxidil is the only drug approved by FDA, used for the treatment of female pattern baldness. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and the use of fertility drugs. According to a 2021 study published on Taylor and Francis online, an American open access journal, the efficacy of ovarian drilling was variable in different literature. Ovulation and pregnancy rates were found to be 30%-90% and 13%-80% respectively. In December 2021, Organon& Co., an American pharmaceutical company working to improve women’s health, acquired Forendo Pharma for $954 million. Through this acquisition Organon plans to bring innovation in the area of women’s health and develop better treatments. Forendo Pharma is a Finland-based clinical stage pharmaceutical company pioneering in the areas of intracrinology and polycystic ovarian syndrome (PCOS). Major players in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott, Addex Therapeutics Ltd., BIOCAD, Allergan PLC., Johnson and Johnson, Ferring BV, and Ferring Pharmaceuticals Inc. North America was the largest region in the polycystic ovarian syndrome treatment market in 2022. Western Europe was the second largest region in the global polycystic ovarian syndrome treatment market. The regions covered in the global polycystic ovarian syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global polycystic ovarian syndrome treatment market is segmented - 1) By Drug Type: Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin-Sensitizing Agents, Anti-Depressants, Diuretics, Aromatase Inhibitors 2) By Surgery Type: Ovarian Wedge Resection, Laparoscopic Ovarian Drilling 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs